regulatory approval

News

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

EU clears Bayer's chronic kidney disease drug Kerendia

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival th

News

GBT claims EU approval for sickle cell drug Oxbryta

Global Blood Therapeutics' run of positive regulatory news for its oral sickle cell disease treatment Oxbryta has continued with an approval for the drug in Europe for patients aged over 12

News

AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Be...

AstraZeneca's Saphnelo has become the first new drug to be approved to treat the autoimmune disease systemic lupus erythematosus (SLE) in the EU for more than 10 years.

News

Sanofi claims FDA okay for drug to treat rare blood disorder...

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

News

Roche grabs FDA okay for would-be blockbuster eye drug faric...

The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.

News

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug

EU clears Bayer's chronic kidney disease drug Kerendia

GBT claims EU approval for sickle cell drug Oxbryta

AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Be...

Sanofi claims FDA okay for drug to treat rare blood disorder...

Roche grabs FDA okay for would-be blockbuster eye drug faric...

Merck gets EU nod for Keytruda in adjuvant kidney cancer

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

regulatory approval

Editor's Picks